The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
Why the study?
Do target-specific oral anticoagulants reduce bleeding complications compared to vitamin K antagonists in patients with venous thromboembolism or atrial fibrillation?
Population
102,607 patients with venous thromboembolism or atrial fibrillation from 12 phase-3 RCTs
Comparison
Target-specific oral anticoagulants (TSOACs) vs Vitamin K antagonists (VKAs)
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
Supports preferring TSOACs over VKAs in AF and VTE; confirms RCT meta-analysis findings on bleeding safety.
Structured PICO
Do target-specific oral anticoagulants reduce bleeding complications compared to vitamin K antagonists in patients with venous thromboembolism or atrial fibrillation?
P
Population
102,607 patients with venous thromboembolism or atrial fibrillation from 12 phase-3 RCTs
I
Intervention
Target-specific oral anticoagulants (TSOACs)
C
Comparator
Vitamin K antagonists (VKAs)
O
Outcome
Overall major bleedingsafety
Target-specific oral anticoagulants are associated with a significantly lower risk of major, fatal, and intracranial bleeding compared to vitamin K antagonists in patients with VTE or AF.
Cite This Study
Chai‐Adisaksopha et al. (2014) studied this question.